Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4617 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C
InChI
InChIKey=RJKFOVLPORLFTN-LEKSSAKUSA-N
InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4617 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2001/75-906_Progesterone_prntlbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8282004
http://www.rxlist.com/endometrin-drug/clinical-pharmacology.htm
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2001/75-906_Progesterone_prntlbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8282004
http://www.rxlist.com/endometrin-drug/clinical-pharmacology.htm
Progesterone is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy. Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization. Common progesterone side effects may include: drowsiness, dizziness; breast pain; mood changes; headache; constipation, diarrhea, heartburn; bloating, swelling in your hands or feet; joint pain; hot flashes; or vaginal discharge.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17015480 |
|||
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17118173 |
|||
Target ID: CHEMBL1994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8282004 |
0.01 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROGESTERONE Approved UseIs indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer. Launch Date2007 |
|||
Primary | PROGESTERONE Approved UseIs indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer. Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60.6 ng/mL |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PROGESTERONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
14.87 ng/mL |
90 mg single, vaginal dose: 90 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
PROGESTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
15.97 ng/mL |
90 mg 1 times / day steady-state, vaginal dose: 90 mg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
PROGESTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
175.7 ng × h/mL |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PROGESTERONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
296.78 ng × h/mL |
90 mg single, vaginal dose: 90 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
PROGESTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
391.98 ng × h/mL |
90 mg 1 times / day steady-state, vaginal dose: 90 mg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
PROGESTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34.8 h |
90 mg single, vaginal dose: 90 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
PROGESTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
45 h |
90 mg 1 times / day steady-state, vaginal dose: 90 mg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
PROGESTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg single, vaginal |
healthy, 32.6 ± 7.3 years n = 10 Health Status: healthy Age Group: 32.6 ± 7.3 years Sex: F Population Size: 10 Sources: |
Other AEs: Drowsiness, Tiredness... Other AEs: Drowsiness (1 patient) Sources: Tiredness (1 patient) Headaches (1 patient) Faint (1 patient) Urinary frequency (1 patient) |
200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
Other AEs: Deep vein thrombosis, Pulmonary embolism... Other AEs: Deep vein thrombosis Sources: Pulmonary embolism Stroke Myocardial infarction Dementia Breast cancer |
400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Other AEs: Fatigue, Headache... Other AEs: Fatigue (8%) Sources: Headache (16%) Dizziness (24%) Diarrhea (8%) Nausea (8%) Back pain (8%) Musculoskeletal pain (12%) Irritability (8%) Breast pain (16%) Coughing (8%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drowsiness | 1 patient | 400 mg single, vaginal |
healthy, 32.6 ± 7.3 years n = 10 Health Status: healthy Age Group: 32.6 ± 7.3 years Sex: F Population Size: 10 Sources: |
Faint | 1 patient | 400 mg single, vaginal |
healthy, 32.6 ± 7.3 years n = 10 Health Status: healthy Age Group: 32.6 ± 7.3 years Sex: F Population Size: 10 Sources: |
Headaches | 1 patient | 400 mg single, vaginal |
healthy, 32.6 ± 7.3 years n = 10 Health Status: healthy Age Group: 32.6 ± 7.3 years Sex: F Population Size: 10 Sources: |
Tiredness | 1 patient | 400 mg single, vaginal |
healthy, 32.6 ± 7.3 years n = 10 Health Status: healthy Age Group: 32.6 ± 7.3 years Sex: F Population Size: 10 Sources: |
Urinary frequency | 1 patient | 400 mg single, vaginal |
healthy, 32.6 ± 7.3 years n = 10 Health Status: healthy Age Group: 32.6 ± 7.3 years Sex: F Population Size: 10 Sources: |
Breast cancer | 200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
|
Deep vein thrombosis | 200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
|
Dementia | 200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
|
Myocardial infarction | 200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
|
Pulmonary embolism | 200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
|
Stroke | 200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Co-administed with:: estrogen Sources: |
unhealthy, 50-79 years Health Status: unhealthy Age Group: 50-79 years Sex: F Sources: |
|
Musculoskeletal pain | 12% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Breast pain | 16% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Headache | 16% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Dizziness | 24% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Back pain | 8% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Coughing | 8% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Diarrhea | 8% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Fatigue | 8% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Irritability | 8% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Nausea | 8% | 400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Age Group: adult Sex: F Population Size: 25 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 10.5 uM] | ||||
yes [IC50 4.8 uM] | ||||
yes [IC50 42.1 uM] | ||||
yes [Inhibition 100 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/9328296/ Page: 3.0 |
yes [Ki 17 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9328296/ Page: 3.0 |
yes [Ki 9 uM] | |||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/19813763/ |
yes | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/9328296/ Page: 5.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9328296/ Page: 5.0 |
yes | |||
yes | ||||
yes | likely (co-administration study) Comment: Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone Sources: https://pubmed.ncbi.nlm.nih.gov/8424894/ |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. | 2000 |
|
Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. | 2001 |
|
The rate-determining step in P450 C21-catalyzing reactions in a membrane-reconstituted system. | 2001 Apr 6 |
|
Dexamethasone up-regulates type II IL-1 receptor in mouse primary activated astrocytes. | 2001 Feb |
|
Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. | 2001 Feb |
|
Endothelins enhance prostaglandin (PGE(2) and PGF(2alpha)) biosynthesis and release by human luteal cells: evidence of a new paracrine/autocrine regulation of luteal function. | 2001 Feb |
|
Action of chicken II GnRH on the human placenta. | 2001 Feb |
|
Adenosine triphosphate-evoked cytosolic calcium oscillations in human granulosa-luteal cells: role of protein kinase C. | 2001 Feb |
|
Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. | 2001 Feb |
|
Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement. | 2001 Feb |
|
Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. | 2001 Feb 1 |
|
Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. | 2001 Feb 7 |
|
Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause. | 2001 Jan |
|
Reliability of ovulation tests in infertile women. | 2001 Jan |
|
Serum allopregnanolone in women with postpartum "blues". | 2001 Jan |
|
Sex steroids and bone. | 2001 Jan |
|
The APC is dispensable for first meiotic anaphase in Xenopus oocytes. | 2001 Jan |
|
Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene. | 2001 Jan |
|
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. | 2001 Jan |
|
Estrogen receptor beta regulates sexually dimorphic neural responses to estradiol. | 2001 Jan |
|
Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. | 2001 Jan |
|
Glucocorticoids regulate plasma membrane potential during rat thymocyte apoptosis in vivo and in vitro. | 2001 Jan |
|
Assessment of mechanisms of thyroid hormone action in mouse Leydig cells: regulation of the steroidogenic acute regulatory protein, steroidogenesis, and luteinizing hormone receptor function. | 2001 Jan |
|
Biphasic action of prolactin in the regulation of murine Leydig tumor cell functions. | 2001 Jan |
|
Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells. | 2001 Jan |
|
Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. | 2001 Jan |
|
Prostaglandin receptors and role of G protein-activated pathways on corpora lutea of pseudopregnant rabbit in vitro. | 2001 Jan |
|
In vitro regulation of local secretion and contraction of the bovine oviduct: stimulation by luteinizing hormone, endothelin-1 and prostaglandins, and inhibition by oxytocin. | 2001 Jan |
|
Granulosa-luteal cell function in vitro and ovarian stimulation protocols. | 2001 Jan |
|
Charcoal treatment and risk of escape ovulation in oral contraceptive users. | 2001 Jan |
|
Reproductive hormones and blood pressure during pregnancy. | 2001 Jan |
|
Hormones and the brain: more studies. | 2001 Jan |
|
Effect of endogenous estrogen on blood flow through carotid arteries. | 2001 Jan |
|
Feed restriction and insulin treatment affect subsequent luteal function in the immediate postovulatory period in pigs: progesterone production in vitro and messenger ribonucleic acid expression for key steroidogenic enzymes. | 2001 Jan |
|
Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia. | 2001 Jan |
|
Increased expression of a novel heat shock protein transcript in the mouse uterus during decidualization and in response to progesterone. | 2001 Jan |
|
Follicle selection in cattle: role of luteinizing hormone. | 2001 Jan |
|
Changes in plasma inhibin A levels during sexual maturation in the female chicken and the effects of active immunization against inhibin alpha-subunit on reproductive hormone profiles and ovarian function. | 2001 Jan |
|
Dexamethasone inhibits luteinizing hormone-induced synthesis of steroidogenic acute regulatory protein in cultured rat preovulatory follicles. | 2001 Jan |
|
Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. | 2001 Jan |
|
Changes in follicle-stimulating hormone and follicle populations during the ovarian cycle of the common marmoset. | 2001 Jan |
|
Follicle-stimulating hormone regulation of inhibin alpha- and beta(B)-subunit and follistatin messenger ribonucleic acid in cultured avian granulosa cells. | 2001 Jan |
|
Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. | 2001 Jan |
|
Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment. | 2001 Jan |
|
The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans. | 2001 Jan 1 |
|
Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. | 2001 Jan 1 |
|
Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. | 2001 Jan 1 |
|
Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. | 2001 Jan 15 |
|
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. | 2001 Jan 3 |
|
Effects of low-frequency magnetic fields on implantation in rats. | 2001 Jan-Feb |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20540763
Curator's Comment: As a resule 34% reduction in cell proliferation was observed in the MB468 cells with treatment of P4, as compared with the cells with treatment of vehicle alone. As expected, P4 had no effects on cell proliferation of the parental MB231. However, the treatment of the mPRα stably-expressing MB231 cells with P4 induced a significant reduction of cell proliferation (28.1%). These data suggest that mPRα is also involved in regulating cell proliferation of BPBC cells.
To test whether the female sex hormone controls cell proliferation of MB468 (basal phenotype breast cancers) cells, cell were incubated the with progesterone (P4) (30 ng/ml) for 24 hours.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:16:58 GMT 2023
by
admin
on
Fri Dec 15 15:16:58 GMT 2023
|
Record UNII |
4G7DS2Q64Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
664818
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
WHO-VATC |
QG03FA04
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
NDF-RT |
N0000005934
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LIVERTOX |
803
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
83109-9
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
82694
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
CFR |
21 CFR 556.540
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
83110-7
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
DSLD |
4218 (Number of products:3)
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
12820-7
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
44729-2
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
CFR |
21 CFR 522.1940
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
24109-1
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
WHO-ATC |
G03FA04
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
14890-8
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/13/1101
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
17483-9
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
WHO-VATC |
QG03DA04
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
CFR |
21 CFR 310.530
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
NDF-RT |
N0000005934
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
44730-0
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
35223-7
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
CFR |
21 CFR 862.1620
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
NCI_THESAURUS |
C2296
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
NDF-RT |
N0000175601
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
NDF-RT |
N0000005934
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
2838-1
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
LOINC |
2839-9
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
WHO-ATC |
G03DA04
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
284809
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2377
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
17026
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
1568007
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
64377
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
PROGESTERONE
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
57-83-0
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL103
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
DTXSID3022370
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
4G7DS2Q64Y
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
5994
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
DB00396
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
D011374
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
100000090354
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
PROGESTERONE
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | Description: Colourless crystals or a white to slightly yellowish white, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 8 parts of ethanol (~750 g/l) TS. Category: Progestational steroid. Storage: Progesterone should be kept in a well-closed container, protected from light. Additional information: Progesterone may exist in 2 polymorphic forms, one of which melts at about 130?C, the other at about 121?C. Definition: Progesterone contains not less than 97.0% and not more than 102.0% of C21H30O2, calculated with reference to the dried substance. | ||
|
m9159
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB10076MIG
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
2279
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
200-350-6
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
Progesterone
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
C777
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
4G7DS2Q64Y
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
417
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
3389
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
9704
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
8727
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
C400424
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY | |||
|
259409
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
ALTERNATIVE | |||
|
Progesterone (medication)
Created by
admin on Fri Dec 15 15:16:58 GMT 2023 , Edited by admin on Fri Dec 15 15:16:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
TARGET -> AGONIST |
IC50
|
||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
ANALOGUE->TARGET |
|
||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
DERIVATIVE -> PARENT | |||
|
ENZYME->SUBSTRATE |
Vmax
|
||
|
AGONIST -> TARGET |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|